Charles River Laboratories Files Second Quarter 10-Q With SEC
The contract research organization submitted its quarterly financial disclosures as investor attention turns to the upcoming earnings call.
Quarterly Filing Submitted
Charles River Laboratories International, Inc. (NYSE: CRL) filed its quarterly report on Form 10-Q with the Securities and Exchange Commission on August 5, 2026, according to regulatory disclosures. The Wilmington, Massachusetts-based contract research organization, which provides drug discovery and development services to pharmaceutical and biotechnology companies, submitted the mandatory filing covering its second quarter financial performance.
The company, with a market capitalization of approximately $11 billion and shares closing at $234.12 in recent trading, operates across preclinical and clinical laboratory services for the life sciences industry.
Earnings Call Scheduled
According to MarginX data, Charles River Laboratories is scheduled to hold its Q2 2026 earnings call on August 5, 2026, coinciding with the 10-Q filing date. The call will provide management commentary on the quarterly results and operational performance during what has been a transformative period for the contract research sector.
Investors and analysts will likely scrutinize the results for insights into demand trends for preclinical services, pricing dynamics, and the company's research model portfolio utilization rates.
Notable Insider Activity
Recent insider transactions have drawn attention, with MarginX data showing that James C. Foster, the company's executive chairman and former CEO, conducted several significant transactions. Foster sold 75,000 shares while also gifting 153,361 shares and an additional 20,000 shares in separate transactions.
While insider sales and gifts can occur for various personal financial planning reasons, such activity is typically monitored by market participants as one of many data points in assessing executive sentiment.
Broader Market Context
The filing comes as market participants await upcoming Federal Reserve decisions, with the FOMC scheduled to announce rate decisions and projections on September 16 and October 28, according to MarginX data. Monetary policy direction remains a key consideration for growth-oriented healthcare and life sciences companies.
This article was generated by MarginX from public news on 2026-08-05. It is not investment advice.